Back to Results
First PageMeta Content
Medicine / Erythropoietic protoporphyria / Science / Clinical research / Design of experiments / Actinic keratosis / Clinical trial / Solar urticaria / Urticaria / Peptide hormones / Afamelanotide / Health


Document Date: 2012-04-19 14:38:08

Open Document

File Size: 107,08 KB

Share Result on Facebook

City

Melbourne / /

Company

Business Operations Europe Clinuvel AG T / Clinuvel Pharmaceuticals Ltd. / CLINICAL TRIAL Clinuvel Pharmaceuticals Limited / Communications Clinuvel Pharmaceuticals Limited T / /

Continent

Australia / Europe / /

Country

Switzerland / Germany / France / United States / Netherlands / Italy / Australia / Sweden / /

/

Event

FDA Phase / /

IndustryTerm

biopharmaceutical / cancer treatment / pharmaceutical / preventative pharmaceutical therapy / /

MedicalCondition

Squamous Cell Carcinoma / cancer / flushing / disease / headache / III PORPHYRIA / phototoxicity / Skin cancer / nausea / pain / Porphyrias / erythropoietic porphyrias / erythropoietic protoporphyria / deficiency / porphyria / disorders / /

MedicalTreatment

Photodynamic Therapy / Organ Transplant / radiation / /

Organization

Congress / Data Safety and Monitoring Board / Monitoring Board / FDA / /

Person

Hank Agersborg / Philippe Wolgen / /

/

Position

CEO / physician / Head / Officer / Chief / /

Product

Insight / SCENESSE® (afamelanotide) / CUV017 / SCENESSE / SCENESSE® / Afamelanotide / /

RadioStation

XETRA / /

Technology

radiation / drug development / /

URL

http /

SocialTag